Expertise in
3
conditions

Dr. Joanna A. Kolodney

Hematology
West Virginia University Hospitals
1 Medical Center Dr, 
Morgantown, WV 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
3
conditions
West Virginia University Hospitals
1 Medical Center Dr, 
Morgantown, WV 

Overview

Joanna Kolodney is a Hematologist practicing medicine in Morgantown, West Virginia.

Dr. Kolodney is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Pediatric Low-Grade Glioma (pLGG), Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, ALK-Positive Non-Small Cell Lung Cancer, and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 23 peer reviewed articles and participating in 11 clinical trials. Dr. Kolodney is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in VA

Hospital Affiliations

Garrett Regional Medical Center
United Hospital Center, Inc
West Virginia University Hospitals, Inc

Languages Spoken

English
Spanish

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Peak Health
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

West Virginia University Hospitals
1 Medical Center Dr, Morgantown, WV 26506

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Drug
Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib
Study Phase: Phase 2
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
An Open-Label, Dose-Escalation Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Modakafusp Alfa (TAK-573) as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
An Open-Label, Dose-Escalation Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Modakafusp Alfa (TAK-573) as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: January 29, 2026
Intervention Type: Drug
Study Drugs: TAK-573, Pembrolizumab
Study Phase: Phase 1/Phase 2
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: January 21, 2026
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drugs: Ipilimumab, IMO-2125
Study Phase: Phase 3
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: September 01, 2022
Intervention Type: Other
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Enrollment Status: Unknown
Publish Date: May 24, 2022
Intervention Type: Drug, Procedure, Radiation
Study Drugs: mFOLFIRINOX, FOLFOX
Study Phase: Phase 2
View 9 Less Clinical Trials

23 Total Publications

Pink Papulonodular Eruption on the Trunk and Arms.
Pink Papulonodular Eruption on the Trunk and Arms.
Journal: Cutis
Published: August 13, 2026
Similar Doctors
Expertise in
19
conditions
Dr. Ashkan Emadi
Hematology
Expertise in
19
conditions
Dr. Ashkan Emadi
Hematology
Referral may be required

West Virginia University Hospitals

1 Medical Center Dr, 
Morgantown, WV 
 (0.1 miles away)
304-598-4500
Languages Spoken:
English, Farsi
See accepted insurances
Accepting New Patients

Ashkan Emadi is a Hematologist practicing medicine in Morgantown, West Virginia. Dr. Emadi is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia, Acute Lymphoblastic Leukemia (ALL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Emadi is currently accepting new patients.

Expertise in
33
conditions
Expertise in
33
conditions
Referral may be required

Mon Health Cancer Center

1200 J D Anderson Dr, 
Morgantown, WV 
 (0.9 miles away)
304-598-6560
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Craig is a Hematologist practicing medicine in Morgantown, West Virginia. Dr. Craig is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Craig is currently accepting new patients.

Expertise in
9
conditions
Expertise in
9
conditions
Referral may be required
Before you request

Classical Hematology

3601 Fifth Ave, Falk Building, 3rd Floor, 
Pittsburgh, PA 
 (54.6 miles away)
412-586-9875
Languages Spoken:
English, Italian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Enrico M. Novelli, MD, is a classical (benign) hematologist, the Chief of the Section of Benign Hematology, and the medical director of the UPMC Adult Sickle Cell Disease Program. Board-certified in hematology, Dr. Novelli received his medical degree from the University of Milan, Italy. He completed his residency in internal medicine and fellowship in hematology-oncology at UPMC. Dr. Novelli specializes in sickle cell anemia and hemoglobinopathies. Dr. Novelli is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, and Hemoglobinopathy. Dr. Novelli is board certified in American Board Of Internal Medicine. Dr. Novelli is currently accepting new patients.

Frequently Asked Questions about Dr. Joanna A. Kolodney

How do I make an appointment with Dr. Joanna A. Kolodney?

You can book an appointment with Dr. Joanna A. Kolodney by calling their office at 304-598-4500. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Joanna A. Kolodney a top-rated expert for Pediatric Low-Grade Glioma (pLGG)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Joanna A. Kolodney is classified as an Advanced expert for Pediatric Low-Grade Glioma (pLGG), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Joanna A. Kolodney specialize in?

While Dr. Joanna A. Kolodney is a Hematology, they have specific expertise in Pediatric Low-Grade Glioma (pLGG), Non-Muscle Invasive Bladder Cancer, and Muscle Invasive Bladder Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Joanna A. Kolodney participate in research or clinical trials?

Yes. Dr. Joanna A. Kolodney has published 23 articles and abstracts on conditions like Pediatric Low-Grade Glioma (pLGG). You can view a list of Dr. Joanna A. Kolodney's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Joanna A. Kolodney accept my insurance?

Dr. Joanna A. Kolodney accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 304-598-4500 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kolodney's expertise for a condition
ConditionClose
      View All 15 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile